12 510(k) Summary for Public Disclosure

12.1 Submitter's Name/Contact Person

Donna R. Lunak

St. Jude Medical

One St. Jude Medical Drive

St. Paul, MN 55117 USA

AUG 2 9 2013

The Establishment Registration Number is 2184149.

12.2 Common or Usual Name

Electrophysiology Mapping System with console and catheter

12.3 Proprietary Name

EnSite Velocity System VeriSense System Software Module v.1.0

12.4 Classification Name

DQK, Programmable diagnostic computer (21 CFR 870.1425), Class II, Cardiovascular Device Panel

12.5 Hardware Description

The EnSite Velocity System consists of the following:

- Display Workstation
- Amplifier

12.6 Predicate Device

The EnSite Velocity System EnSite Velocity System v.3.0 (K112688)

12.7 Indications for Use

Device Name: EnSite Velocity System

The EnSite Velocity™ Cardiac Mapping System is a suggested diagnostic tool in patients for whom electrophysiology studies are indicated.

When used with the EnSite Array™ Catheter, the EnSite Velocity System is intended to be used in the right atrium of patients with complex arrhythmias that may be difficult to identify using conventional mapping systems alone.
OR
When used with the EnSite NavX™ Surface Electrode Kit, the EnSite System is intended to display the position of conventional electrophysiology catheters in the heart.

Device Name: VeriSense System Software

VeriSense™ Technology is intended for monitoring catheter tip-to-tissue electrical coupling, which may be indicative of catheter tip-to-tissue contact during cardiac electrophysiology procedures via a proprietary Electrical Coupling Index (ECI).

12.8 Device Comparison to the Predicate Device

EnSite Velocity System with VeriSense System Software Module has the same indications for use and fundamental scientific technology as the predicate device, EnSite Velocity System v.3.0 (K112688). All technological characteristics of the EnSite Velocity System with VeriSense System Software Module are substantially equivalent to the predicate device, EnSite Velocity System v.3.0 (K112688).

12.9 Summary of Non-Clinical Testing

Bench testing was performed to confirm that the changes met design requirements and did not affect the safety or effectiveness of the product.

12.10 Summary of Clinical Testing

A final clinical report of the CONTACT AFL study (conducted under a prospective, multi-center and non-randomized IDE pivotal study (IDE# G110026)) was submitted to support approval of PMA supplement (P11016/S007) for the VeriSense System hardware and VeriSense Enabled Catheters and a summary of the clinical study applicable to the diagnostic portion (VeriSense Software) is included under this 510k as requested by the FDA via teleconference on October 11, 2012.

A summary report of the Electrical Coupling Index (ECI) Validation that was collected from the CONTACT AFL Study is included in Section 29.

12.11 Summary of Design Control Activities

The development of the EnSite Velocity System VeriSense System Software Module was performed in accordance with St. Jude Medical's Quality System requirements, and in compliance with Quality System Regulation design controls requirements documented in 21 CFR 820.30. A Declaration of Conformity with Design Controls follows in section 13.4. The reviewer should note that during development, the EnSite Velocity System VeriSense System Software Module was referred to as EnSite Velocity System v.4.0 Contact/VeriSense Module.

12.12 Conclusion

As in the use of the predicate device EnSite Velocity System v.3.0 (K112688), EnSite Velocity System VeriSense System Software Module has the same fundamental scientific technology as the predicate device, EnSite Velocity System v.3.0 (K112688). All technological characteristics of the EnSite Velocity System with VeriSense System Software Module are substantially equivalent to the predicate device, EnSite Velocity System v.3.0 (K112688).

Where operational and performance differences exist between the proposed device and the predicate device, performance testing demonstrated that these differences do not adversely affect the device's safety and effectiveness.

Therefore, St. Jude Medical considers the EnSite Velocity System VeriSense System Software Module to be substantially equivalent to the predicate device, EnSite Velocity System v.3.0 (K112688).

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-002

August 29, 2013

St. Jude Medical
Ms. Donna Lunak
One St. Jude Medical Drive
St. Paul, MN 55117 US

Re: K130727
Trade/Device Name: Ensite velocity system
Regulation Number: 21 CFR 870.1425
Regulation Name: Electrophysiology Mapping System
Regulatory Class: Class II
Product Code: DQK
Dated: August 5, 2013
Received: August 6, 2013

Dear Ms. Donna Lunak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, Misbranding by reference to premarket notification (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htmfor the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Owen P Faris -S

for

Bram D. Zuckerman, Ph.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

7 Indications for Use

Device Name: EnSite Velocity System

Indications for Use:

The EnSite Velocity™ Cardiac Mapping System is a suggested diagnostic tool in patients for whom electrophysiology studies are indicated.

- When used with the EnSite Array™ Catheter, the EnSite System is intended to be used in the right atrium of patients with complex arrhythmias that may be difficult to identify using conventional mapping systems alone.

OR

- When used with the EnSite NavX Surface Electrode Kit, the EnSite System is intended to display the position of conventional electrophysiology (EP) catheters in the heart.

Device Name: VeriSense System Software

Indications for Use:

VeriSense™ Technology is intended for monitoring catheter tip-to-tissue electrical coupling, which may be indicative of catheter tip-to-tissue contact during cardiac electrophysiology procedures via a proprietary Electrical Coupling Index (ECI).

Prescription Use ___X___ (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use _____ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Digitally signed by Owen P. Faris -S
Date: 2013.08.29 10:40:54 -04'00'